6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
Bleeding O
, O
including O
life-threatening O
and O
fatal O
bleeding O
, O
is O
the O
most O
commonly O
reported O
adverse O
reaction O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bristol-Myers O
Squibb/Sanofi O
Pharmaceuticals O
Partnership O
at O
1-800-633-1610 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
and O
durations O
of O
follow-up O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Plavix O
has O
been O
evaluated O
for O
safety O
in O
more O
than O
54,000 O
patients O
, O
including O
over O
21,000 O
patients O
treated O
for O
one O
year O
or O
more O
. O

The O
clinically O
important O
adverse O
reactions O
observed O
in O
trials O
comparing O
Plavix O
plus O
aspirin O
to O
placebo O
plus O
aspirin O
and O
trials O
comparing O
Plavix O
alone O
to O
aspirin O
alone O
are O
discussed O
below O
. O

Bleeding O
CURE O
In O
CURE O
, O
Plavix O
use O
with O
aspirin O
was O
associated O
with O
an O
increase O
in O
major O
bleeding B-OSE_Labeled_AE
( I-OSE_Labeled_AE
primarily I-OSE_Labeled_AE
gastrointestinal I-OSE_Labeled_AE
and O
at O
puncture O
sites O
) O
compared O
to O
placebo O
with O
aspirin O
( O
see O
Table O
1 O
) O
. O

The O
incidence O
of O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.1 O
% O
) O
and O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
( O
0.2 O
% O
) O
were O
the O
same O
in O
both O
groups O
. O

Other O
bleeding B-OSE_Labeled_AE
events O
that O
were O
reported O
more O
frequently O
in O
the O
clopidogrel O
group O
were O
epistaxis B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
bruise B-OSE_Labeled_AE
. O

The O
overall O
incidence O
of O
bleeding B-NonOSE_AE
is O
described O
in O
Table O
1 O
. O

Table O
1 O
: O
CURE O
Incidence O
of O
Bleeding B-OSE_Labeled_AE
Complications O
( O
% O
patients O
) O
Event O
Plavix O
( O
+ O
aspirin O
) O
( O
n=6259 O
) O
Placebo O
( O
+ O
aspirin O
) O
( O
n=6303 O
) O
Major O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Life-threatening O
and O
other O
major O
bleeding B-OSE_Labeled_AE
. O
] O

3.7 O
2.7 O
Life-threatening O
bleeding B-OSE_Labeled_AE
2.2 O
1.8 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
5 O
g/dL O
hemoglobin B-OSE_Labeled_AE
drop I-OSE_Labeled_AE
0.9 O
0.9 O
Requiring O
surgical O
intervention O
0.7 O
0.7 O
Hemorrhagic B-OSE_Labeled_AE
strokes I-OSE_Labeled_AE
0.1 O
0.1 O
Requiring O
inotropes O
0.5 O
0.5 O
Requiring O
transfusion O
( O
> O
=4 O
units O
) O
1.2 O
1.0 O
Other O
major O
bleeding B-OSE_Labeled_AE
1.6 O
1.0 O
Significantly O
disabling O
0.4 O
0.3 O
Intraocular B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
with O
significant O
loss B-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
0.05 O
0.03 O
Requiring O
2-3 O
units O
of O
blood O
1.3 O
0.9 O
Minor O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Led O
to O
interruption O
of O
study O
medication O
. O
] O

5.1 O
2.4 O
COMMIT O
In O
COMMIT O
, O
similar O
rates O
of O
major O
bleeding B-OSE_Labeled_AE
were O
observed O
in O
the O
Plavix O
and O
placebo O
groups O
, O
both O
of O
which O
also O
received O
aspirin O
( O
see O
Table O
2 O
) O
. O

Table O
2 O
: O
Incidence O
of O
Bleeding O
Events O
in O
COMMIT O
( O
% O
patients O
) O
Type O
of O
Bleeding B-OSE_Labeled_AE
Plavix O
( O
+ O
aspirin O
) O
( O
n=22961 O
) O
Placebo O
( O
+ O
aspirin O
) O
( O
n=22891 O
) O
p-value O
Major O
[ O
note O
: O
Major O
bleeds O
were O
cerebral O
bleeds O
or O
noncerebra B-OSE_Labeled_AE
l I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
-OSE_ O
Labeled B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
bleeds I-OSE_Labeled_AE
thought O
to O
have O
caused O
death B-NonOSE_AE
or O
that O
required O
transfusion O
. O
] O

noncerebral B-OSE_Labeled_AE
or O
cerebral O
bleeding I-OSE_Labeled_AE
0.6 O
0.5 O
0.59 O
Major O
noncerebral O
0.4 O
0.3 O
0.48 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
0.90 O
Hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
0.2 O
0.2 O
0.91 O
Fatal B-NonOSE_AE
0.2 O
0.2 O
0.81 O
Other O
noncerebral B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
( O
nonmajor O
) O
3.6 O
3.1 O
0.005 O
Any O
noncerebral B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
3.9 O
3.4 O
0.004 O
CAPRIE O
( O
Plavix O
vs O
Aspirin O
) O
In O
CAPRIE O
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
occurred O
at O
a O
rate O
of O
2.0 O
% O
in O
those O
taking O
Plavix O
versus O
2.7 O
% O
in O
those O
taking O
aspirin O
; O
bleeding B-OSE_Labeled_AE
requiring O
hospitalization O
occurred O
in O
0.7 O
% O
and O
1.1 O
% O
, O
respectively O
. O

The O
incidence O
of O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
0.4 O
% O
for O
Plavix O
compared O
to O
0.5 O
% O
for O
aspirin O
. O

Other O
bleeding B-OSE_Labeled_AE
events O
that O
were O
reported O
more O
frequently O
in O
the O
Plavix O
group O
were O
epistaxis B-OSE_Labeled_AE
and O
hematoma B-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
In O
CURE O
and O
CHARISMA O
, O
which O
compared O
Plavix O
plus O
aspirin O
to O
aspirin O
alone O
, O
there O
was O
no O
difference O
in O
the O
rate O
of O
adverse O
events O
( O
other O
than O
bleeding B-NonOSE_AE
) O
between O
Plavix O
and O
placebo O
. O

In O
CAPRIE O
, O
which O
compared O
Plavix O
to O
aspirin O
, O
pruritus B-OSE_Labeled_AE
was O
more O
frequently O
reported O
in O
those O
taking O
Plavix O
. O

No O
other O
difference O
in O
the O
rate O
of O
adverse O
events O
( O
other O
than O
bleeding B-NonOSE_AE
) O
was O
reported O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
Plavix O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
an O
unknown O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hemorrhages B-OSE_Labeled_AE
, O
including O
those O
with O
fatal B-NonOSE_AE
outcome O
, O
have O
been O
reported O
in O
patients O
treated O
with O
Plavix O
. O

* O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
/ O
pancytopenia B-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
, O
acquired B-OSE_Labeled_AE
hemophilia I-OSE_Labeled_AE
A I-OSE_Labeled_AE
* O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Colitis B-OSE_Labeled_AE
( O
including O
ulcerative B-OSE_Labeled_AE
or O
lymphocytic O
colitis I-OSE_Labeled_AE
) O
, O
pancreatitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
/duodenal O
ulcer I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
* O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
condition I-NonOSE_AE
: O
Fever B-OSE_Labeled_AE
* O
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
( O
noninfectious I-OSE_Labeled_AE
) O
, O
abnormal B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
* O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
* O
Musculoskeletal B-NonOSE_AE
, I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
and I-NonOSE_AE
bone I-NonOSE_AE
disorders I-NonOSE_AE
: O
Myalgia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Taste B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
ageusia B-OSE_Labeled_AE
* O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Confusion B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
* O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Bronchospasm B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
pneumonitis I-OSE_Labeled_AE
, O
eosinophilic B-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
* O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
Increased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Maculopapular B-OSE_Labeled_AE
, O
erythematous O
or O
exfoliative O
rash I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
exanthematous I-OSE_Labeled_AE
pustulosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AGEP I-OSE_Labeled_AE
) I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
DRESS B-OSE_Labeled_AE
) O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
lichen B-OSE_Labeled_AE
planus I-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
pruritus I-OSE_Labeled_AE
* O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE

